Markers of Polyfunctional SARS-CoV-2 Antibodies in Convalescent Plasma
Abstract
Convalescent plasma has been deployed globally as a treatment for COVID-19, but efficacy has been mixed. Better understanding of the antibody characteristics that may contribute to its antiviral effects is important for this intervention as well as offer insights into correlates of vaccine-mediated protection.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Apr 27, 2021
- Source ID
- 10.1128/mbio.00765-21
Entities
People
- Aaron Tobian
- Andrew D. Redd
- Andrew Pekosz
- Andrew R Crowley
- Arturo Casadevall
- David P Sullivan
- Evan M Bloch
- H. Benjamin Larman
- Harini Natarajan
- Joshua A Weiner
- Kirsten Littlefield
- Margaret E. Ackerman
- Oliver Laeyendecker
- Peter F. Wright
- Ruth I. Connor
- Sarah E. Benner
- Savannah E. Butler
- Shiwei Xu
- Shmuel Shoham
- Tania S. Bonny
- Thomas C. Quinn
- Wendy Wieland-alter
Organizations
- Dartmouth College
- Geisel School of Medicine
- Johns Hopkins Bloomberg School of Public Health
- Johns Hopkins School of Medicine
- National Institute of Allergy and Infectious Diseases
- National Institutes of Health
- United States Department of Defense